Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
Authors:
- 18 January 2018
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 14 (4) , 391-407
Abstract
Breast cancer is the most common malignancy among women and accounts for the second highest number of cancer-related deaths. With patients surviving longer due to advances in systemic control, the incidence of CNS involvement is increasing; however, the management of CNS metastases has not undergone parallel advancements. The blood–brain barrier limits the efficacy of most systemic chemotherapies, and the utilization of surgery and radiation beyond first-line therapy is limited. We will explore the recent developments in the medical management of breast cancer brain metastasis. Beyond traditional chemotherapy, we will also discuss targeted therapies and immunotherapies which may provide a survival benefit to this population and thus, offer further treatment options and a path for future research and treatment advances.Keywords
Funding Information
- Northwestern University Feinberg School of Medicine
This publication has 84 references indexed in Scilit:
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesJournal of Neuro-Oncology, 2011
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patientsJournal of Neuro-Oncology, 2009
- A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastasesJournal of Neuro-Oncology, 2007
- Capecitabine Therapy of Central Nervous System Metastases from Breast CancerJournal of Neuro-Oncology, 2007
- Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinomaCancer, 2006
- Systemic high-dose intravenous methotrexate for central nervous system metastasesJournal of Neuro-Oncology, 2005
- Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II studyJournal of Neuro-Oncology, 2005
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997